Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

- Strong commercial launch underway with LIVMARLI® (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of launch, total 2021 company revenue of $19.1 million

- Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022

- Conference call to provide business updates today, March 9 at 1:30 p.m. PT/4:30 p.m. ET

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2021 and provided a business update.

“2021 marked a significant turning point for Mirum and the Alagille syndrome community. With a strong start to our launch of LIVMARLI, the first and only FDA-approved medication for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older, we achieved fourth quarter 2021 net product revenue of $3.1 million,” said Chris Peetz, president and chief executive officer at Mirum. “We expect continued growth in prescriptions and reimbursement as we unlock LIVMARLI’s potential both in the United States and globally. In addition to our growing topline, we look forward to generating data from all five of our late-stage pipeline indications over the coming two years.”

2021 Highlights

Fourth Quarter

• Launched LIVMARLI in the United States, the first and only medicine approved for cholestatic pruritus in patients with Alagille syndrome one year of age and older.
• Sold Rare Pediatric Disease Priority Review Voucher (PRV), granted by the U.S. Food and Drug Administration (FDA) in September 2021 in connection with the approval of LIVMARLI, for $110.0 million.
• Presented late-breaking oral presentation on six-year natural history comparison with LIVMARLI showing event-free survival (p